Showing results (71-80 of 161) with videos related to
Sort By:
Pageof 17
Journal of Drugs in Dermatology : JDD|January 4, 2011
Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar linesKenneth R Beer, Charles Boyd, Rina K Patel, et al.Headache|April 20, 2005
Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled studyDavid W Dodick, Alexander Mauskop, Arthur H Elkind, et al.The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry|July 28, 2018
Amyloid Plaques of Alzheimer's Disease as Hotspots of Glutamatergic ActivitySaak V Ovsepian, Valerie B O'Leary, Laszlo Zaborszky, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 2, 2018
Synaptic vesicle cycle and amyloid β: Biting the hand that feedsSaak V Ovsepian, Valerie B O'Leary, Laszlo Zaborszky, et al.The Biochemical Journal|May 22, 2014
Targeted delivery of a SNARE protease to sensory neurons using a single chain antibody (scFv) against the extracellular domain of P2X(3) inhibits the release of a pain mediatorHui Ma, Jianghui Meng, Jiafu Wang, et al.Current Opinion in Pharmacology|April 28, 2009
Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeuticsJ Oliver Dolly, Gary W Lawrence, Jianghui Meng, et al.Clinical Neuropharmacology|September 6, 2012
Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystoniaDavid Charles, Allison Brashear, Robert A Hauser, et al.International Clinical Psychopharmacology|October 15, 2019
OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult femalesMitchell F Brin, Suresh Durgam, Arlene Lum, et al.Cephalalgia : an International Journal of Headache|March 25, 2022
Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSDAndrew M Strassman, Agustin Melo-Carrillo, Timothy T Houle, et al.Cephalalgia : an International Journal of Headache|November 17, 2020
Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neuronsAgustin Melo-Carrillo, Andrew M Strassman, Aaron J Schain, et al.Pageof 17